BeiGene receives European Commission approval for BRUKINSA

BeiGene announced that the European Commission has granted marketing authorization for BRUKINSA in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior lines of systemic therapy. This marks the fourth indication in the European Union for BRUKINSA, which is now approved to treat more patient populations in the EU than any other Bruton’s tyrosine kinase inhibitor.